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receptorAbstract Pharmacophore modeling, molecular docking and in silico ADME prediction have been
performed for quinazoline based EGFR inhibitors. This study has been carried out to determine
the binding mode and drug likeliness nature of compounds. A five point model (AAARR.7) was gen-
erated using 64 compounds. The generated model was found to be statistically significant as it had a
high correlation coefficient (R2 = 0.9433), cross validation coefficient (Q2 = 0.8493) and F value of
97.10 at 6 component PLS factor. The results of external validation were also indicative of high pre-
dictive power (R2 = 0.86). The generated model also passed Tropsha’s test for predictive ability and
Y-randomization test. TheDomain of Applicability (APD) of the model was also successfully defined
to ascertain that a given prediction can be considered reliable. In order to evaluate the effectiveness of
the docking protocol, co-crystallized ligand was extracted from the ligand binding domain of the pro-
tein and was re-docked into the same position. The conformer obtained on re-docking and the co-
crystallized ligand were superimposed and the root mean square deviation between the twowas found
to be 1.005 A˚. Outcomes of this study provide an insight for designing novel EGFR inhibitors.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tion; A,
h factor
hibitors.
2 G. Verma et al.1. Introduction
Cancer is one of the leading causes of death in both developing and
developed countries (Han et al., 2016). The total number of new cancer
cases is projected to increase from 14 million in 2012 to 24 million in
2035 (Liu et al., 2016). Despite the availability of a broad range com-
pounds, cancer therapy still has many limitations. Side effects and
resistance to the current agents are the major ones (Pape et al.,
2016). These factors necessitate the need for development of novel
and safer anticancer agents.
The Epidermal Growth Factor Receptor (EGFR), a member of
ErbB family which signals through a tyrosine kinase (TK) is involved
in regulation of growth, migration and apoptosis of tumor cells (Yan
et al., 2015). It has been described in the nucleus of primary tumors
(Rodrigues et al., 2016). Hence, it is considered as one of the important
targets for the development of novel anticancer agents.
EGFR inhibitors, such as gefitinib and erlotinib have made signif-
icant progress in the treatment of patients with cancer (Johnson et al.,
2005; Ciardiello and Tortora, 2008). Gefitinib and erlotinib inhibit the
tyrosine kinase activity by competitively binding to the adenosine
triphosphate (ATP) binding pocket of the intracellular EGFR TK
domain, thereby blocking downstream signal transduction pathways
in cancer cells. However, the success of such EGFR tyrosine kinase
inhibitors is limited by the up-regulation of bypass signaling pathways
and acquired point mutations (Oxnard et al., 2011). After treatment of
10–16 months with these inhibitors, most of the cancer patients acquire
an additional gate keeper mutation (T790M) (Kobayashi et al., 2005).
The secondary T790M mutation decreases sensitivity to gefitinib or
erlotinib and increases the binding affinity for ATP (Ou, 2012). In
order to overcome the T790M mutation related resistance, several irre-
versible EGFR second-generation covalent inhibitors, which form a
covalent bond with Cys797 within the EGFR active site, have shown
preclinical activity against EGFR with T790M mutation (Xia et al.,
2014). Afatinib was the first approved irreversible EGFR inhibitor
by the US FDA for the treatment of late-stage cancer patients with
actively mutated EGFR. Other examples include canertinib and
dacomitinib (Dungo and Keating, 2013).
Structural information provided by the co-crystal structures of gefi-
tinib or erlotinib (Yun et al., 2007; Stamos et al., 2002) with EGFR has
played a major role in rational design of potent EGFR inhibitors.
Analysis of binding mode of gefitinib suggests various key interactions
with the ATP binding pocket of EGFR, including the critical hydrogen
bond of the N1 of the quinazoline moiety with the hinge residue Met
793 of active site, the deep hydrophobic pocket filled up by the 3-
chloro-4-fluoro aniline substituent and the solvent region occupation
of 6-morpholinopropoxy group. A variety of polar functional groups
are generally accommodated with a little affection on the efficacy by
the solvent region (Yin et al., 2014). A good example of this strategy
is the success of icotinib, which mimics erlotinib with a crown ether
fused quinazoline (Liu et al., 2015; Guan et al., 2014).
The EGFR kinase domain adopts a bilobate-fold and characteristic
NH2 terminal lobe (N-lobe) is composed of mainly b-strands and a-
helix. COOH lobe (C-lobe) is mostly a-helical. These two lobes are sep-
arated by a cleft, similar to the one possessed by ATP. ATP analogs
and ATP competitive inhibitors are known to bind in this cleft. Cat-
alytic machinery of N-lobe includes glycine-rich nucleotide phosphate
binding loop (Gly 695 – Gly 700). C-lobe comprises of DFG motif
(Asp 831 – Gly 833), presumptive catalytic loop (Asp 813), the cat-
alytic loop (Arg 812 – Asn 818) and the A-loop (Asp 831 – Val852).
However, Erlotinib, an approved EGFR inhibitor is found in the cleft
between the N- and C-terminal lobes (Stamos et al., 2002).
Emergence of resistance and side effects of the currently used
agents further push the scientists across the globe to engage themselves
in the development of novel EGFR targeting agents (Tang et al., 2013;
Costa et al., 2008; Zheng et al., 2014). Nowadays, computational stud-
ies based on ligand- and structure-based approaches, are considered
effective tools in medicinal chemistry, useful to accelerate the drugPlease cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
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Fossa, 2012). With these facts, we herein report the pharmacophore
modeling, 3D-QSAR, molecular docking and ADME prediction of
quinazoline analogs to provide an insight into the key structural fea-
tures required for designing EGFR targeting agents.
2. Materials and methods
2.1. Data set
A set comprising of 64 compounds bearing quinazoline moiety
were selected from the available literatures (Qin et al., 2016a,
2016b; Qin et al., 2015). The selected compounds for the data
set shared the same assay procedure with significant variations
in their structures and potency profiles. Inhibitory potencies of
the compounds included in data set, reported as IC50 values
varied from 2.0 to 16,500 nM and were converted into molar
values. These were then converted into pIC50 values using
the formula given below:
pIC50 ¼ log10½IC50
The 3D structures of ligands were generated using the builder
panel in Maestro and subsequently optimized using LigPrep
module (v3.1, Schro¨dinger 2016-1). Partial atomic charges
were ascribed and possible ionization states were generated
at a pH of 7.0. The OPLS_2005 force field was used for opti-
mization for production of low energy conformer of the ligand
(Shivakumar et al., 2010). The energy minimization was per-
formed for each ligand till it reached a root mean square devi-
ation (RMSD) cutoff of 0.01 A˚. The resulting structures were
then taken for performing modeling studies. In the current
study, we used phase (v4.0) shape screening for flexible align-
ment of the selected EGFR inhibitors.
2.2. Pharmacophore 3D-QSAR modeling
Phase (v4.6, Schro¨dinger 2016-1) was used to generate phar-
macophore and 3D-QSAR models for EGFR inhibitors
(Dixon et al., 2006). The prepared ligands were imported for
developing pharmacophore model panel of Phase with their
respective biological activity values. The ligands were assigned
as actives with a threshold of pIC50 > 7.7 and inactives with a
threshold of pIC50 < 6.0. Remaining compounds were consid-
ered as moderately active. Phase (v4.0) has been proven to be
an important tool for flexible ligand superposition (Sastry
et al., 2011; Miller et al., 1999). In the current study, we used
phase (v4.0) shape screening for flexible alignment of the
selected EGFR inhibitors. The most active compound 3 was
taken as the template and pharmacophore type volume scoring
was kept as default. The default settings were used, with a
maximum of 10 conformations per rotatable bonds and with
this a maximum of 100 conformers were generated. Conforma-
tions of these compounds were varied and at most one align-
ment for every ligand was retained.
The selection of training and test sets is the most important
and also the most difficult step, which often consumes much
time in building QSAR models. Random division is a widely
used approach in establishing the QSAR model robustness
(Wang et al., 2015). Therefore, for assigning training and test
set for 64 compounds, random selection was made using the
Automated Random Selection option present in Phase (v4.0)SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
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were run. The trials were based on structural diversity and a
wide range of activity – the range of biological activity of the
test-set molecules was similar to that of the training set. Thus,
the test set chosen was a true representative of the training set,
as per recommendations of Golbraikh and Tropsha, 2003.
Resultantly, 20 compounds were included in the test set and
remaining 44 compounds were included in training set. Phar-
macophore sites for these compounds included default set of
chemical features of Phase: three hydrogen bond acceptors
(A) and two aromatic rings (R). Pharmacophore matching tol-
erance was set as 1 A˚. A total of 19 variants were generated by
keeping 5 and 4 as the maximum and minimum number of
sites respectively. It was specified that at least 9 of the actives
must match. Finally, it resulted in 12 possible combinations of
features which could give rise to common pharmacophores.
2.3. Model validation
The QSAR model AAARR.7 with 6 component PLS factor
was characterized as the best model. Pharmacophoric model
was validated by its accuracy in prediction of the activity of
training set ligands. The predicted EGFR inhibitory activity
of training set ligands elicited a correlation (R2) of 0.85 with
observed EGFR inhibitory activity. The efficacy of model
AAHR.11 was also examined with external validation (Table 1:
Supplementary Material and Fig. 4). Graph of actual value vs.
predicted value and residual value vs. predicted value was
plotted.
The predictive power of the produced 3D-QSAR model
was also assessed by using Enalos Model Acceptability Criteria
KNIME node (Melagraki and Afantitis, 2013), which includes
all proposed tests by Tropsha (Zhang et al., 2006). Criteria fol-
lowed in developing activity/property predictors, especially for
continuous QSAR, are as follows: (i) correlation coefficient R
between the predicted and observed activities; (ii) coefficients
of determination (predicted versus observed activities R0
2 and
observed versus predicted activities R00
2 for regressions through
the origin); and (iii) slopes k and k0 of regression lines through
the origin. The criterions for the acceptability of the QSAR
model are represented in left column of Fig. 5.
2.4. Domain of applicability
In order to screen a QSAR model for new compounds, its
domain of application (APD) (Tropsha et al., 2003; Shen
et al., 2004) must be defined and predictions for only those
compounds that fall into this domain may be considered reli-
able. Extent of Extrapolation (Tropsha et al., 2003) and Eucli-
dean Distances are two simple approaches to define the APD.
Extent of Extrapolation is based on the calculation of the
leverage (hi) for each chemical, where the QSAR model is used
to predict its activity.
hi ¼ xiðXTXÞ1xTi
In the above equation, xi is the row vector containing the k
model parameters of the query compound and X is the n  k
matrix containing the k model parameters for each one of
the n training compounds. A leverage value greater than
3k/n is considered large. It means that the predicted responsePlease cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
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may not be reliable.
APD can also be defined using similarity measurements
based on the Euclidean distances among all training and test
compounds. The distance of a test compound to its nearest
neighbor in the training set is compared to a predefined thresh-
old (APD), and the prediction is considered unreliable when
the distance is higher than that. APD was calculated based
on the following formula:
APD ¼ hdi þ Zr
Calculation of hdi and r was performed as follows: first, the
average of Euclidean distances between all pairs of training
compounds was calculated. Next, the set of distances that were
lower than the average was formulated. hdi and r were finally
calculated as the average and standard deviation of all dis-
tances are included in this set. Z is an empirical cutoff value
and for this work, it was chosen as 0.5 (Zhang et al., 2006).
Enalos Domain – similarity node that executes the aforemen-
tioned procedure was included in our workflow and used to
assess domain of applicability of the proposed model. For
the calculation of the domain of applicability, we have used
Enalos Domain KNIME nodes.
2.5. Y-randomization test
Y-Randomization technique ensures the robustness of a
QSAR model (Tropsha et al., 2003; Shen et al., 2004). The
dependent variable vector is randomly shuffled and a new
QSAR model is developed, using the given modeling algo-
rithm. The procedure is repeated several times and the new
QSAR models are expected to have low R2 and Q2 values. If
the opposite happens then an acceptable QSAR model cannot
be obtained for the specific modeling method and data.
2.6. Molecular docking
The catalytic domain of EGFR enzyme in complex with erlo-
tinib (PDB Code: 1M17 resolution 2.6 A˚) was obtained from
protein data bank (Stamos et al., 2002) and prepared using
the protein preparation wizard (Sastry et al., 2013), available
in Schro¨dinger suite 2016-1. Crystallographic water molecules
i.e. without 3H bonds were deleted and hydrogen bonds corre-
sponding to pH 7 were added considering the appropriate ion-
ization states for both acidic and basic amino acid residues.
OPLS_2005 force field was used for energy minimization of
the crystal structure (Shivakumar et al., 2010). Active site
was defined with a radius of 14 A˚ around the ligand present
in crystal structure. Grid box was generated at a centroid of
active site. For docking, low energy conformations of all the
compounds were docked into the catalytic domain of EGFR
protein (PDB Code: 1M17) using Grid based Ligand Docking
with Energetics (Glide v7.0, Schro¨dinger 2016-1) (Lipinski
et al., 2001) in extra precision mode without applying any con-
straints. The best docked structure was identified using Glide
score function, Glide energy and Glide Emodel energy
(Table 2: Supplementary Material). The lowest energy docked
compound 3 was selected for further studies. A map of
hydrophobic and hydrophilic fields for inhibitor 3 was also
generated (Fig. 8).SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
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prediction
We further predicted the drug-like behavior of the compounds
through the analysis of pharmacokinetic profile of the com-
pounds by using QikProp module (v4.3, Schro¨dinger 2016-1).
The compounds prepared by LigPrep module (v3.1, Schro¨din-
ger 2016-1) were utilized for the calculation of pharmacoki-
netic parameters by QikProp v4.3. The program QikProp
v4.3, utilizes the method of Jorgensen19 to compute pharma-
cokinetic properties and descriptors. Physically significant
descriptors and pharmaceutically relevant properties of all
the test compounds such as molecular weight, log p, H-bond
donors, and H-bond acceptors according to the Lipinski’s rule
of five were analyzed. Lipinski’s rule of five is a rule of thumb
to evaluate drug likeness, or determine whether a chemical
compound with a certain pharmacological or biological activ-
ity has properties that would make it a likely orally active drug
in humans. The rule describes molecular properties important
for drug pharmacokinetics in the human body, including its
absorption, distribution, metabolism and excretion (ADME)
(Cheng et al., 2014).
3. Results and discussion
3.1. Pharmacophore and 3D-QSAR models
Phase (v4.0) (Dixon et al., 2006) module of Schro¨dinger 2016-1
was used for the development of pharmacophore model. Atom
based 3D-QSAR unveiled the effect of substituents on activity.
The generated hypotheses were scored and ranked in accor-
dance with their vector, volume, site scores, survival scoresTable 1 Score of different parameters of the hypotheses.
S. No. Hypothesis Survival score Survival inactive
1 AAARR.7 6.202 4.215
2 AAARR.25 5.816 4.310
3 AAARR.94 5.755 4.249
4 AAARR.23 5.444 3.929
5 AAARR.24 5.398 3.656
6 AAARR.19 5.388 3.664
7 AAARR.93 5.388 3.664
8 AAARR.95 5.354 3.356
9 AAARR.96 5.354 3.356
A: Acceptor; R: Aromatic ring.
Table 2 PLS statistical parameters of the model AAARR.7.
PLS SD R2 F P
1 0.6002 0.5030 40.50 1.459e007
2 0.5052 0.6568 37.30 8.758e010
3 0.3623 0.8280 61.00 1.373e014
4 0.3046 0.8816 68.90 1.237e016
5 0.2531 0.9205 83.30 9.158e019
6 0.2167 0.9433 97.10 2.468e020
SD: Standard deviation of regression;R2: Regression coefficient; F: Rati
ratio); P: Significance level of variance ratio; Q2: Cross validated correla
predictions.
Please cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
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Based on the sites, a maximum of five features were allowed
for developing the hypotheses. 3D-QSAR model was gener-
ated using Partial Least Square (PLS) regression statistics
and keeping the grid spacing of 1 A˚. The number of PLS fac-
tors included in model development is 6 because an incremen-
tal increase in the statistical significance and predictivity was
observed till 6 PLS factor (Table 2).
The best fittedmodel AAARR.7 (R2 = 0.9433,Q2 = 0.8493
and F= 97.10) consists of three hydrogen bond acceptors and
two aromatic ring features with highest survival score (6.202).
The hypothesis AAARR.7 is shown in Fig. 1. The distance
and angles between different sites of the model AAARR.7 are
presented in Tables 3 and 4 respectively. This is also apparent
from the comparison from the deduction of survival inactive
from survival active. It deducts inactive features from the
hypothesis and was decisively highest for the hypothesis
AAARR.7. Among the pharmacophore features, intersite
distances and angles between site points were found to be the
principal attribute and the point of difference between active
and inactive is due to the interstitial site distances as evident
by the pharmacophore hypothesis AAARR.7alignment over
active (pIC50 > 7.7) and inactive compounds (pIC50 < 6.0) in
Fig. 2a and b respectively. Using the model, AAARR.7, fitness
score of all the ligands was also evaluated (Table 5).
3.2. Model validation, domain of applicability and Y-
randomization test
The predictability and validity of the common pharmacophore
model, AAARR.7 (test set), based on active compounds were
judged by cross validation coefficient (Q2 = 0.84) (Table 2).Site Vector Matches Activity Inactive
1.00 1.000 9 8.036 1.988
0.68 0.859 9 8.036 1.507
0.66 0.838 9 8.036 1.507
0.50 0.797 9 7.963 1.514
0.41 0.826 9 8.699 1.743
0.47 0.797 9 7.963 1.723
0.47 0.797 9 7.963 1.723
0.44 0.779 9 8.174 1.998
0.44 0.779 9 8.174 1.998
Stability RMSE Q2 Pearson-R
0.9624 0.6358 0.5582 0.7619
0.9717 0.5333 0.6891 0.8370
0.8017 0.3744 0.8468 0.9320
0.7706 0.3791 0.8429 0.9260
0.7523 0.3804 0.8418 0.9222
0.7013 0.3713 0.8493 0.9244
o of the model variance to the observed activity variance (variance
tion coefficient for the test set; RMSE: the RMS error in the test set
SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
Figure 1 Hypothesis, AAARR.7. Pink spheres with arrow, hydrogen bond acceptor (A); orange open circle, aromatic ring (R).
Table 3 Angles between the pharmacophoric sites of
AAARR.7.
Entry Site 1 Site 2 Distance
AAARR.7 A3 A4 2.821
AAARR.7 A3 A5 4.800
AAARR.7 A3 R12 3.747
AAARR.7 A3 R13 2.798
AAARR.7 A4 A5 2.682
AAARR.7 A4 R12 5.056
AAARR.7 A4 R13 2.788
AAARR.7 A5 R12 5.055
AAARR.7 A5 R13 2.803
AAARR.7 R12 R13 2.422
Table 4 Intersite distances between the pharmacophoric sites
of AAARR.7.
Entry Site 1 Site 2 Site 3 Angle
AAARR.7 A4 A3 A5 28.5
AAARR.7 A4 A3 R12 99.7
AAARR.7 A4 A3 R13 59.5
AAARR.7 A5 A3 R12 71.3
AAARR.7 A5 A3 R13 31.0
AAARR.7 R12 A3 R13 40.3
AAARR.7 A3 A4 A5 121.4
AAARR.7 A3 A4 R12 46.9
AAARR.7 A3 A4 R13 59.9
AAARR.7 A5 A4 R12 74.6
AAARR.7 A5 A4 R13 61.6
AAARR.7 R12 A4 R13 13.0
AAARR.7 A3 A5 A4 30.1
AAARR.7 A3 A5 R12 44.6
AAARR.7 A3 A5 R13 31.0
AAARR.7 A4 A5 R12 74.7
AAARR.7 A4 A5 R13 61.1
AAARR.7 R12 A5 R13 13.6
AAARR.7 A3 R12 A4 33.4
AAARR.7 A3 R12 A5 64.1
AAARR.7 A3 R12 R13 48.3
AAARR.7 A4 R12 A5 30.8
AAARR.7 A4 R12 R13 15.0
AAARR.7 A5 R12 R13 15.8
AAARR.7 A3 R13 A4 60.7
AAARR.7 A3 R13 A5 118.0
AAARR.7 A3 R13 R12 91.4
AAARR.7 A4 R13 A5 57.3
AAARR.7 A4 R13 R12 152.1
AAARR.7 A5 R13 R12 150.6
Quinazoline based EGFR inhibitors 5Regression coefficient of the training set was 0.94, which
exhibited relevance of the model. Stability of the generated
model ranges from 0.7013 to 0.9624 on the maximum scale
of 1. F value was found to be 97.10. Additionally, P value of
2.468e020 and Pearson r of 0.9244 indicated greater degree
of confidence on the model. Standard deviation (SD) value
of 0.2167 and root mean square error (RMSE) of 0.3713 indi-
cate the stability of the generated model for prediction of
unknown compounds in the test. Scatter plots for experimental
and predicted activities of ligands elicited significant linear cor-
relation and moderate difference between the experimental and
predicted values as shown in Fig. 3a and b. In order to evalu-
ate the efficacy of the generated model, it was further validated
using an external test set (Golbraikh and Tropsha, 2002a). The
calculated pIC50 values of the compounds included in pre-
dicted and external test set are given in Table 5 and Table 1
(Supplementary Material) respectively. A plot of experimental
vs. predicted pIC50 of external test set is shown in Fig. 4a and aPlease cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
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Figure 2 (a) Mapping of the active compounds onto the pharmacophore. (b) Mapping of inactive compounds onto the pharmacphore.
6 G. Verma et al.plot of residual vs. predicted value is shown in Fig. 4b. These
two plots are vital for the predictive ability of QSAR. Scatter
residual plots were used to identify the outliers from the QSAR
model (Golbraikh and Tropsha, 2002b). Fig. 4b elicits that
there is no outlier in the study. Thereby, the model is consid-
ered as stable and as expected. It was able to sort the experi-
mental pIC50 values for compounds in the external test set.
Predictive correlation coefficient R2 value of 0.86 was observed
for the external test set for the developed QSAR model. An R2
value of more than 0.5 between the predicted and experimental
values renders the model to be good and able to predict the
inhibitory activity of compounds not included in the model
development process (Golbraikh and Tropsha, 2002a, 2002b).
Furthermore, the Enalos Model Acceptability Criteria
KNIME node has also been applied to the data. The model
passed Tropsha’s recommended tests for predictive ability
and the results are depicted in Fig. 5. These results suggest that
this alignment can effectively take into consideration the
ligand-receptor interactions, and the QSAR model is thus reli-Please cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.019able and could be used in the design of new EGFR inhibitors
within this structural motif of molecules.
It is important that the limitations of the model are also
described via the APD. This gives an important indication as
the user can freely and creatively design novel molecules but
will be warned for the reliability of the prediction when the
structural characteristics cannot be tolerated by the model.
After model validation, the APD of our model was also
defined to ascertain that a given prediction can be considered
reliable. Enalos Domains – Similarity (Euclidean Distances)
and Leverage (Extent of Extrapolation) nodes that execute
the aforementioned procedure are included in our workflow
and were used to assess APD of the proposed model. In Eucli-
dean Distances method, the APD limit value was defined equal
to 0.633, whereas in Extent of Extrapolation method, the APD
limit was defined as 0.15. These limits were defined on the basis
of equations provided in Methods section. In both types of
APD prediction, all compounds in the test set had values in
the range of the APD. The predictions for all compounds thatSAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
Table 5 Calculated pIC50 for compounds in predicted set.
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
1t
O
N
N NH
F
Cl
O
O
7.64 7.82 0.18 2.56
2
O
N
N NH
O
O
7.96 8.02 0.06 2.56
3t
O
N
N NH
F
Cl
O
O
8.69 8.26 0.40 3.00
4t
NH
O
O
O
N
N
8.03 7.81 0.22 2.58
5
O
NH
O
O
O
N
N
8.35 8.22 0.13 2.81
(continued on next page)
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
6
O
N
N NH
Cl
O
O 8.17 8.32 0.15 2.59
7
O
N+
NH
O
O
O
N
N
O-
8.01 8.10 0.09 2.98
8t
O
O
N
N NH
F
Cl
O
O 7.88 7.12 0.76 2.56
9
NH
O
O
O
N
N
7.67 7.79 0.12 2.94
8 G. Verma et al.
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
10
O
O
N
N NH
F
O
O 6.69 6.90 0.21 2.57
11
O
NH
O
O
O
O
N
N
6.79 6.70 0.09 2.94
12
O
O
N
N NH
F
N+
O-
O
O
O 7.35 6.86 0.49 2.52
13t
ON
+
NH
O
O
O
O
N
N
O-
7.12 6.84 0.28 2.74
(continued on next page)
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
14t
O
O
N
N NH
Cl
N+
O-
O
O
O 7.44 6.82 0.62 2.53
15
N
NH
O
O
O
O
N
N
F
6.41 6.52 0.11 2.77
16
F
NH
O
O
O
O
N
N
Cl
7.61 7.46 0.15 2.83
17
NH
O
O
O
O
N
N
7.56 7.45 0.11 2.90
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
18
O
N
N NH
F
N+
O-
O
O
O
7.08 7.30 0.22 2.53
19t
ON
+
NH
O
O
O
N
N
O-
6.73 7.32 0.59 2.94
20t
O
N
N NH
Cl
N+
O-
O
O
O
6.98 7.31 0.33 2.53
21
N
NH
O
O
O
N
N
F
6.50 6.88 0.38 2.78
22t
N
NH
O
O
O
N
N
6.38 7.12 0.74 2.96
(continued on next page)
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
23
O
N
N NH
F
Cl
O
O
7.53 7.51 0.02 2.57
24
O
N
N NH
O
O 7.62 7.70 0.08 2.56
25
O
N+
NH
O
O
O
O
N
N
F O-
6.63 6.57 0.06 2.87
26
O
N+
NH
O
O
O
O
N
N
-O
6.44 6.52 0.08 2.88
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
27
N
NH
O
O
O
O
N
N
F
6.45 6.25 0.20 2.89
28t
F
NH
O
O
O
O
N
N
Cl
6.60 6.85 0.25 2.86
29
NH
O
O
O
O
N
N
6.32 6.66 0.34 2.76
30t
F
NH
O
O
O
O
N
N
Cl
7.68 7.55 0.13 2.83
(continued on next page)
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
31
NH
O
O
O
O
N
N
7.77 7.53 0.24 2.89
32
O
N
N NH
F
Cl
O
O
O
7.23 7.05 0.18 2.55
33t
O
N
N NH
O
O
O
7.23 7.24 0.01 2.54
34t
F
NH
O
O
O
N
O
N
N
Cl
7.58 7.49 0.09 2.66
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
35
Br
NH
O
O
O
N
O
N
N
7.73 7.40 0.33 2.68
36
Cl
NH
O
O
O
N
O
N
N
7.65 7.39 0.26 2.68
37
F
NH
O
O
O
N
O
N
N
7.07 7.44 0.37 2.68
38
F
NH
O
O
O
N
O
N
N
F
F
7.01 7.21 0.20 2.78
(continued on next page)
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
39
ON
N
O
N
N
H
F N O
6.61 6.60 0.01 1.36
40
ON
N
O
NH
Cl
N
N O
7.20 7.20 0.00 1.39
41t
ON
N
O
NH
Br
N
N O
7.04 7.19 0.15 1.39
42
ON
N
O
NH
N
N O
6.72 6.84 0.12 1.37
43
ON
N
O
NH
F
FF
N
N O
6.08 6.23 0.15 1.35
44
ON
N
O
NH
N
N O
6.85 6.57 0.28 1.36
45
ON
N
O
NH
F
Cl
N
N O
7.27 6.94 0.33 1.36
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
46
ON
N
O
NH
F
N
N O
6.36 6.48 0.12 1.39
47t
ON
N
O
NH
Cl
N
N O
6.45 6.39 0.06 1.37
48
ON
N
O
NH
Br
N
N O
6.08 6.33 0.25 1.37
49t
ON
N
O
NH
N
N O
6.22 6.31 0.09 1.37
50
ON
N
O
NH
N
N O
6.28 6.17 0.11 1.38
51
ON
N
O
NH
Cl
N
N O
6.78 6.62 0.16 1.36
52t
ON
NH+
NH
F
N
N O
6.33 6.51 0.18 1.37
(continued on next page)
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
53
ON
NH+
NH
Cl
N
N O
6.93 6.77 0.16 1.37
54
ON
NH+
NH
Br
N
N O
7.00 6.83 0.17 1.37
55
ON
NH+
NH
N
N O
6.341 6.61 0.27 1.37
56t
ON
NH+
NH
N
N O
6.67 6.82 0.15 1.36
57
ON
NH+
NH
F
Cl
N
N O
6.86 6.98 0.12 1.37
58
ON
O
F
O
ON
O
N
4.98 4.89 0.09 1.97
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Table 5 (continued)
Ligand name Chemical structure Experimental activity Predicted activity Residual activity Fitness
59t
ON
O
O
ON
O
N
5.15 4.94 0.21 1.98
60
ON
F
O
ON
O
N
5.06 5.07 0.01 2.01
61
ON
O
ON
O
N
4.78 5.09 0.31 2.02
62
ON
F
FF
O
ON
O
N
5.05 5.03 0.02 1.97
63
ON
O
O
ON
O
N
4.99 5.05 0.06 2.00
64t ON
F
O
ON
O
N
5.00 5.58 0.58 1.098
t test.
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Figure 3 Scatter plot of the observed versus phase-predicted
activity for (a) training set (y= 0.94x+ 0.39, R2 = 0.94) and (b)
test set compounds with best fit line (y= 0.79x+ 1.46,
R2 = 0.85).
Figure 4 (a) Plot of actual value vs. predicted value of external
training set (y= 1.20x+ (2.08), R2 = 0.86). (b) Plot of residual
value vs predicted value.
Figure 5 Screenshot of results obtained by Enalos Model
Acceptability Criteria KNIME node.
20 G. Verma et al.fell inside the domain of applicability of the model can be con-
sidered reliable.
The model was further validated by applying Y-
randomization. Several random shuffles of the Y vector were
performed and the low R2 and Q2 values that were obtained
show that the good results in the original model use not due
to a chance correlation or structural dependency of the train-
ing set. It should be noted that for each random permutation
of the Y vector, the complete training procedure was followedPlease cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.019for developing the new QSAR model, including the selection of
the most appropriate descriptors. The results of the Y-
randomization test are presented in Table 3 (Supplementary
Material).SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
Quinazoline based EGFR inhibitors 213.3. 3D-QSAR contour map analysis
Contour plot analysis was performed to identify the effect of
spatial arrangement of structural features such as electrostatic,
ionic, hydrophobic, H-bond donor and H-bond acceptor
regions on antitubulin activity. Their individual positive con-
tribution is shown in blue cubes and negative contribution is
indicated by red cubes. Fig. 6a–e shows the comparison of
most significant favorable and unfavorable interactions, whichFigure 6 QSAR model visualized in the context of favorable and unfa
(b) compound 61 (4.78). QSAR model visualized in the context of favo
(8.69) and (d) compound 61 (4.78). QSAR model visualized in the conte
compound 3 (8.69) and (f) compound 61 (4.78).
Please cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.019arise on the application of QSAR model to the most active and
least active ligands.
The hydrogen-bond donor nature for the most active com-
pound 3 (Fig. 6a) and the least active compound 61 (Fig. 6b)
when compared showed their most favorable region with blue
color and unfavorable regions with red color. Hydrogen-bond
donor mapping revealed that favorable regions lied near the
amine group of aniline present at fourth position of quinazo-
line (Fig. 6a), indicating their importance for activity as com-vorable hydrogen bond donor effects in (a) compound 3 (8.69) and
rable and unfavorable hydrophobic interactions in (c) compound 3
xt of favorable and unfavorable electron withdrawing groups in (e)
SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
22 G. Verma et al.pared to the least active compound 61, devoid of amine group
at the same steric position (Fig. 6b). Therefore, the presence of
aniline with hydrogen donor amine group is vital for the
EGFR inhibitory activity. This assumption is further sup-
ported by the less activity of non-aniline containing com-
pounds 58–64, when compared to all other aniline containing
compounds 1–57. The presence of blue cubes near the oxygen
(at A3 pharmacophoric feature) of dioxane ring attached to
the fifth and sixth carbon position of quinazoline indicates
its importance for activity as compared to the least active com-
pound 61, devoid of the ring in its backbone structure.
The 3-morpholinopropyl derivatives (39–42 and 44–45)
showed higher potency values than the related 3-(piperidin-1-
yl)propyl analogs (52–57). This indicates that the increased
hydrophilicity of 6-position substituent of quinazoline may
be beneficial for enhancing the inhibitory activity against
EGFR.
The comparison between the electron withdrawing group
effects of the most and least active compounds can be seenFigure 7 (a) Binding mode of compound 3 in the catalytic pocket of 1
of 1M17. (c) Hydrophobic interactions of 3 in the catalytic pocket of
crystal structure conformation (cyan).
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is a big blue region at the aforementioned position indicating
preference of electron withdrawing group substitution over
it. This observation is consistent with trend of activity that
when the meta position of aniline attached to quinazoline is
substituted with electron-withdrawing group such as nitro or
cyano in compounds 12–15, the activity decreased dramati-
cally. Similarly, among compounds 18–29 substituted with sec-
ondary carbon chain at seventh position of quinazoline,
compounds 18–22 and 25–27, with the same electron with-
drawing (nitro or cyano) substitution at meta position of ani-
line exhibited 10 times less potency against EGFR than the
most active compound 3.
3.4. Molecular docking
The scores of docking studies are shown in Table 2 (Supple-
mentary Material). From 63 listed total-scores, pIC50 of mostM17. (b) 2D-ligand interaction diagram of 3 in the catalytic pocket
1M17. (d) Overlay of docked pose (magenta) of Erlotinib with its
SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
Figure 8 Map of hydrophobic and hydrophilic fields for
inhibitor 3 into the catalytic protein of EGFR (1M17).
Figure 9 Superimposition of conformations of inhibitor 3: best
docking pose and pose of the AAARR.7 model (RMSD: 1.005 A˚).
Quinazoline based EGFR inhibitors 23compounds keep in touch with the Glide score. Docking study
revealed that interactions were dominated by the hydrophobic-
ity and aromaticity due to the presence of quinazoline moiety.
The interactions were dominated in the region of Met 769, Leu
694, Phe 699, Pro 770, Phe 771 and Cys 773 amino acid residue
content due to pronounced existence of active site in the region
(Fig. 7a and b). In general, quinazoline ring exhibited
hydrophobic interactions with Ile 765, Ala 719, Met 769,
Leu 694, and Leu 768 the key residues necessary for binding
of inhibitors (Fig. 7c). 1,4-Dioxane ring, attached to quinazo-
line ring showed hydrophobic interactions with Phe 699, Val
702, Cys 773, and Phe 771. Phenyl ring substituted with fluoro
and chloro groups, attached to quinazoline ring via NH link-
age exhibited hydrophobic interactions with Phe 832, Leu
764, Leu 753, Met 742, Ile 720 and Ile 765. It also had polar
interactions with Thr 830 and Thr 766 residues. A hydrogen
bond of 2.14 A˚ was also seen in case of quinazoline ring with
Met 769, as shown in Fig. 7c with pink color. This is also evi-
dent by analyzing the generated map of hydrophobic and
hydrophilic fields for inhibitor 3 (Fig. 8), quinazoline moiety,
a part of 1,4-dioxane, and phenyl ring are buried in the
hydrophobic pocket (orange color) and some parts of 1,4-
dioxane and phenyl ring are in hydrophilic pocket (cyan
color). Our Glide XP-docking result also revealed solvent
exposure in the region of 1,4-dioxane and ethoxy substitution
plays an important role in stabilization of inhibitor at the
active site.
In addition, the accuracy of the docking procedure is deter-
mined by examining how closely the lowest energy poses (bind-
ing conformation) predicted by the object scoring function,
and Glide score (GScore) almost resembles an experimental
binding mode as determined by X-ray crystallography. The
root mean square deviation (RMSD) between the predicted
conformation and the observed X-ray crystallographic confor-
mation of colchicines (PDB Code: 1M17) equal to 1.0057 A˚
(Fig. 7d), a value that suggests the reliability of Glide XP dock-
ing mode in reproducing the experimentally observed binding
mode of EGFR inhibitors and the parameter set for Glide
XP docking are reasonable to reproduce the X-ray structure.
Further, similar orientation was observed between the super-
position of conformation 3 best XP-docking pose and 3D-
QSAR pose (RMSD: 1.005 A˚) (Fig. 9).
3.5. Lipinski’s rule for drug likeliness and in silico ADME
prediction
Different pharmacokinetic parameters of the compounds
taken for the study were calculated using ADME predictions
by QikProp v4.3. The compounds were assessed for their basic
parameters of Lipinski’s rule of 5 and other pharmacokinetic
parameters. Table 4 (Supplementary Material) shows the
results obtained from QikProp with their permissible range.
In general, an orally active compound should not have more
than 2 violations of the Lipinski rule. The active test com-
pounds in present study were not found to violate the rule
more than the maximum permissible limits and thus proving
their drug likeness properties.
The optimum values of the descriptors, polar surface area
and rotatable bonds also have great influence on the oral
bioavailability of the drug molecules. The important parame-
ters with their permissible ranges are delineated in Table 4Please cite this article in press as: Verma, G. et al., Pharmacophore modeling, 3D-Q
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.019(Supplementary Material). The optimum value of rotatable
bonds (0–15) and polar surface area (7–200 A˚) holds a great
importance on the oral bioavailability of the drug molecules.
The active test quinazoline derivatives demonstrated results
of the descriptors to be in the prescribed range thus owing
good bioavailability. Intestinal absorption or permeation is
also one of the important factors to be studied in concern with
the absorption of the drug molecule, which was further con-
firmed by predicted Caco-2 cell permeability (QPPCaco), used
as model for gut–blood barrier. Caco-2 cell permeability pre-
diction of the test compounds indicates excellent results pre-SAR, docking and ADME prediction of quinazoline based EGFR inhibitors.
24 G. Verma et al.dicting good intestinal absorption. Further, the test results for
QPlogkhsa descriptor of QikProp indicating the predicted val-
ues of human serum albumin binding indicated that test mole-
cules were found to fall in the permissible range (1.5 to 1.5).
Also, the QikProp descriptor for blood/brain partition coeffi-
cient QPlogBB showed reliable prediction for all the test com-
pounds and reference drugs. The cell permeability of the blood
brain barrier mimic MDCK cells (QPPMDCK) also displayed
reliable results falling in the prescribed range. The aqueous sol-
ubility parameter (QPlog S) of the test entities was assessed
and the compounds were also found to be in the permissible
range (<0.5).
4. Conclusion
Combined computational approach was applied to give an insight into
the structural basis and inhibition mechanism for a series of quinazo-
line derivatives as EGFR inhibitors. 3D-QSAR modeling was per-
formed to provide a structural framework for understanding the
structure activity relationship of these compounds. The atom based
3D-QSAR generated model AAARR.7 exhibited good correlation
and predictive power and satisfactory agreement between experiment
and theory. Molecular docking studies were performed to produce pos-
sible binding poses for these compounds to EGFR. The low value of
RMSD between the initial complex structure and the energy minimized
final average complex structure suggests that the derived docked com-
plex is close to equilibrium. Further, ADME predictions were per-
formed for these compounds.
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